Layers cagrilintide's amylin-pathway satiety signal onto retatrutide's triple GLP-1/GIP/glucagon mechanism to hit four non-overlapping metabolic pathways at once — the aim is greater total fat loss, more complete appetite control, and the option to run each compound at a lower, better-tolerated dose.
Why it matters
Retatrutide alone hits three appetite-and-metabolism pathways at once; cagrilintide adds a fourth, separate "fullness" pathway (amylin) that acts in a different part of the brain.
The published per-compound doses, timing, cycle length, the mechanism sources give for why it's combined, and the harm-reduction notes — the parts that took the most research to get right — are part of membership.
